Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F.

O. Vornicova,D. Hershkovitz,T. Yablonski-Peretz,O. Ben‐Itzhak,Z. Keidar,G. Bar-Sela
DOI: https://doi.org/10.1634/theoncologist.2014-0054
2014-09-01
The Oncologist
Abstract:Extramammary Paget’s disease is a rare intraepithelial malignant condition affecting the apocrine gland-bearing skin. In this case, a genomic alteration, ERBB2 S310F mutation, was discovered. The ERBB2 S310F mutation seems to be a transforming mutation that should be targeted with anti-HER2 drugs. Genomic tests are justified in rare tumors.
What problem does this paper attempt to address?